Rishabh Sethia1, Ali C Yumusakhuylu2,3, Isa Ozbay4,3, Virginia Diavolitsis5, Nicole V Brown6, Songzhu Zhao6, Lai Wei6, Matthew Old3,7, Amit Agrawal3,7, Theodoros N Teknos3,7, Enver Ozer3,7. 1. College of Medicine, The Ohio State University, Columbus, Ohio, U.S.A. 2. Department of Otolaryngology-Head and Neck Surgery, Marmara University Faculty of Medicine, Istanbul, Turkey. 3. Department of Otolaryngology-Head and Neck Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, U.S.A. 4. Department of Otolaryngology, Dumlupinar University, Kutahya, Turkey. 5. Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, U.S.A. 6. Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio, U.S.A. 7. Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, Columbus, Ohio, U.S.A.
Abstract
OBJECTIVES/HYPOTHESIS: To compare quality of life (QOL) of patients who underwent transoral robotic surgery (TORS) alone, with adjuvant radiation therapy (RT), or adjuvant chemoradiation therapy (CRT) in the treatment of oropharyngeal squamous cell cancer (OPSCCA). STUDY DESIGN: Prospective cohort study. METHODS: Medical records were reviewed for 111 patients treated for OPSCCA from 2008 to 2015. Patients were administered the Head and Neck Cancer Inventory (HNCI) to evaluate QOL preoperatively, and at 3 weeks, 3 months, 6 months, and 1 year postsurgery. QOL data were compared between 13 patients treated with TORS alone, 31 with adjuvant RT, and 67 with adjuvant CRT by a linear mixed effects model. RESULTS: Mean follow-up was 35 months. The HNCI response rates at 3 weeks and 3, 6, and 12 months were 80%, 60%, 55%, and 46%, respectively. TORS alone reported significantly higher eating scores than adjuvant RT or CRT at 3 and 6 months, and higher speech scores compared to adjuvant CRT at 3 months and adjuvant RT at 6 months. TORS alone and adjuvant RT reported less social disruption compared to adjuvant CRT at 3 months. Adjuvant CRT had consistently lower overall QOL scores until 6 months. No TORS-alone patient required percutaneous endoscopic gastrostomy, and no study patient required tracheostomy during treatment. CONCLUSIONS: TORS alone maintained higher QOL than adjuvant RT or CRT in eating, social function, speech, and overall QOL postsurgery. QOL and functional metrics were better for 6 months in TORS-alone patients, and at 12 months, the differences were not significant. LEVEL OF EVIDENCE: 4. Laryngoscope, 128:403-411, 2018.
OBJECTIVES/HYPOTHESIS: To compare quality of life (QOL) of patients who underwent transoral robotic surgery (TORS) alone, with adjuvant radiation therapy (RT), or adjuvant chemoradiation therapy (CRT) in the treatment of oropharyngeal squamous cell cancer (OPSCCA). STUDY DESIGN: Prospective cohort study. METHODS: Medical records were reviewed for 111 patients treated for OPSCCA from 2008 to 2015. Patients were administered the Head and Neck Cancer Inventory (HNCI) to evaluate QOL preoperatively, and at 3 weeks, 3 months, 6 months, and 1 year postsurgery. QOL data were compared between 13 patients treated with TORS alone, 31 with adjuvant RT, and 67 with adjuvant CRT by a linear mixed effects model. RESULTS: Mean follow-up was 35 months. The HNCI response rates at 3 weeks and 3, 6, and 12 months were 80%, 60%, 55%, and 46%, respectively. TORS alone reported significantly higher eating scores than adjuvant RT or CRT at 3 and 6 months, and higher speech scores compared to adjuvant CRT at 3 months and adjuvant RT at 6 months. TORS alone and adjuvant RT reported less social disruption compared to adjuvant CRT at 3 months. Adjuvant CRT had consistently lower overall QOL scores until 6 months. No TORS-alone patient required percutaneous endoscopic gastrostomy, and no study patient required tracheostomy during treatment. CONCLUSIONS:TORS alone maintained higher QOL than adjuvant RT or CRT in eating, social function, speech, and overall QOL postsurgery. QOL and functional metrics were better for 6 months in TORS-alone patients, and at 12 months, the differences were not significant. LEVEL OF EVIDENCE: 4. Laryngoscope, 128:403-411, 2018.
Authors: Daniel J Ma; Katharine A Price; Eric J Moore; Samir H Patel; Michael L Hinni; Joaquin J Garcia; Darlene E Graner; Nathan R Foster; Brenda Ginos; Michelle Neben-Wittich; Yolanda I Garces; Ashish V Chintakuntlawar; Daniel L Price; Kerry D Olsen; Kathryn M Van Abel; Jan L Kasperbauer; Jeffrey R Janus; Mark Waddle; Robert Miller; Satomi Shiraishi; Robert L Foote Journal: J Clin Oncol Date: 2019-06-04 Impact factor: 44.544
Authors: Diane W Chen; Tao Wang; Jonathan Shey-Sen Ni; Vlad C Sandulache; Evan M Graboyes; Mitchell Worley; Joshua D Hornig; Judith M Skoner; Terry A Day; Andrew T Huang Journal: Oral Oncol Date: 2019-03-28 Impact factor: 5.337
Authors: Andrew J Holcomb; Matthew Herberg; Madeleine Strohl; Edgar Ochoa; Allen L Feng; Nicholas B Abt; Tara E Mokhtari; Krish Suresh; Christopher I McHugh; Anuraag S Parikh; Peter Sadow; William Faquin; Daniel Faden; Daniel G Deschler; Mark A Varvares; Derrick T Lin; Carole Fakhry; William R Ryan; Jeremy D Richmon Journal: Head Neck Date: 2021-04-15 Impact factor: 3.821
Authors: Benjamin H Kann; Sanjay Aneja; Gokoulakrichenane V Loganadane; Jacqueline R Kelly; Stephen M Smith; Roy H Decker; James B Yu; Henry S Park; Wendell G Yarbrough; Ajay Malhotra; Barbara A Burtness; Zain A Husain Journal: Sci Rep Date: 2018-09-19 Impact factor: 4.379
Authors: G Meccariello; F Montevecchi; G D'Agostino; G Iannella; S Calpona; E Parisi; M Costantini; G Cammaroto; R Gobbi; E Firinu; R Sgarzani; D Nestola; C Bellini; A De Vito; E Amadori; C Vicini Journal: Acta Otorhinolaryngol Ital Date: 2019-04 Impact factor: 2.124
Authors: Jean-Jacques Stelmes; Vincent Gregoire; Vincent Vander Poorten; Wojciech Golusiñski; Mateusz Szewczyk; Terry Jones; Mohssen Ansarin; Martina A Broglie; Roland Giger; Jens Peter Klussmann; Mererid Evans; Jean Bourhis; C René Leemans; Giuseppe Spriano; Andreas Dietz; Keith Hunter; Frank Zimmermann; Ingeborg Tinhofer; Joanne M Patterson; Silvana Quaglini; Anne-Sophie Govaerts; Catherine Fortpied; Christian Simon Journal: Front Oncol Date: 2019-10-22 Impact factor: 6.244